Enveric Biosciences, Inc. (ENVB) Key Metrics
ENVB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.2M
- Enterprise value
- −$1.4M
- P/E (TTM)
- —
- Forward P/E
- 23.1
- PEG ratio
- —
- Price / sales
- 0.1
- Price / book
- 0.9
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 1.18
ENVB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsENVB returns How much profit the business earns on the capital it uses.
ENVB financial health Debt, liquidity and how easily interest is covered.
ENVB efficiency & capital use Working capital cycle and where the cash goes.
ENVB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ENVB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ENVB cash returned to shareholders
ENVB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $3.63 | $64.51 | $234.00 | $374.40 | $8,370.00 | $38,340.00 | $81,360.00 | $156,960.00 | $2,790,000.00 | $5,859,000.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −420.5% | −539.6% | −0.2% | −97.7% | −380.8% | −97.8% | −52.4% | −111.9% | −58.3% | −46.6% |
| Return on invested capital (ROIC) | — | — | — | — | −346.1% | −40.7% | −33.7% | −31.1% | −51.1% | −43.0% |
| Return on assets (ROA) | −296.7% | −259.4% | −0.1% | −80.0% | −317.9% | −47.2% | −20.5% | −41.3% | −19.8% | −10.4% |
| Return on tangible assets | −238.1% | −314.9% | −0.4% | −96.5% | −269.0% | — | −72.9% | −166.8% | −43.6% | −20.4% |
| Free cash flow margin | — | — | — | — | — | −9.9% | −1.6% | −6.0% | −5.7% | −17.7% |
| Financial health | ||||||||||
| Total debt | — | — | — | $63,820 | $176,303 | $4.9M | $4.9M | $5.2M | $7.2M | $5.0M |
| Cash & short-term investments | $4.7M | $2.2M | $2.3M | $17.7M | $17.4M | $1.6M | $431,400 | $1.4M | $4.9M | $1.5M |
| Net debt | −$4.7M | −$2.2M | −$2.3M | −$17.7M | −$17.2M | $3.3M | $4.4M | $3.8M | $2.3M | $3.6M |
| Debt / equity | — | — | — | 0.00 | 0.01 | 1.43 | 0.46 | 0.48 | 0.37 | 0.43 |
| Debt / assets | — | — | — | 0.00 | 0.01 | 1.19 | 0.20 | 0.18 | 0.14 | 0.13 |
| Current ratio | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 | 3.35 | 0.53 | 0.68 | 0.48 | 0.79 |
| Quick ratio | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 | 3.35 | 0.53 | 0.68 | 0.48 | 0.79 |
| Interest coverage | — | — | — | — | — | -12.6 | -9.2 | -9.8 | -20.8 | -7.2 |
| Working capital | $4.0M | $1.2M | $1.2M | $14.4M | $15.7M | $1.6M | −$6.8M | −$4.6M | −$15.7M | −$2.6M |
| Invested capital | −$499,950 | −$648,219 | −$331,641 | −$2.1M | $5.1M | $6.7M | $15.1M | $14.6M | $21.7M | $15.2M |
| Tangible asset value | $4.2M | $1.6M | $1.7M | $15.2M | $13.8M | −$12.1M | −$6.7M | −$8.7M | −$11.9M | −$14.2M |
| Net current asset value | $4.0M | $1.2M | $1.2M | $14.4M | $13.3M | $1.6M | −$6.8M | −$8.8M | −$18.1M | −$17.8M |
| Capital allocation | ||||||||||
| Dividends paid | $3.4M | — | — | — | — | — | — | $2.09T | $2.09B | — |
| Share buybacks (net) | — | $0 | $1.1M | $0 | — | — | — | $0 | — | — |
| Capex / revenue | — | — | — | — | — | 0.1% | 0.2% | 0.4% | 0.0% | 10.2% |
| Capex / depreciation | 0.00 | 0.00 | 0.01 | 1.34 | 1.27 | 0.37 | 0.04 | 0.07 | 0.00 | 2.71 |
| Stock-based compensation / revenue | — | — | — | — | — | 5.0% | 1.5% | 2.9% | 14.6% | 4.0% |
| R&D / revenue | — | — | — | — | — | 0.4% | — | — | — | — |
| SG&A / revenue | — | — | — | — | — | 13.6% | 30.6% | 25.1% | 38.1% | 24.8% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 58.4 | 65.2 | 70.9 | 63.5 | 65.3 |
| Days payables outstanding | 1,002.0 | 941.2 | 752.3 | 480.9 | 365.4 | 8,119.4 | 52.1 | 52.1 | 49.7 | 47.6 |
| Cash conversion cycle (days) | — | — | — | — | — | -8,061.1 | 13.0 | 18.9 | 13.7 | 17.7 |
| Receivables turnover | — | — | 0.00 | — | — | 6.25 | 5.60 | 5.15 | 5.75 | 5.59 |
| Payables turnover | 0.36 | 0.39 | 0.49 | 0.76 | 1.00 | 0.04 | 7.00 | 7.01 | 7.34 | 7.66 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.74 | 1.46 | 1.05 | 1.06 | 1.36 |
| Average receivables | — | — | $224,607 | — | — | $6.4M | $7.1M | $8.4M | $8.4M | $6.5M |
| Average payables | $551,384 | $870,265 | $841,029 | $573,334 | $682,322 | $2.7M | $4.5M | $4.9M | $5.2M | $3.9M |
| Intangibles / total assets | 0.0% | 1.4% | 4.9% | 1.9% | 31.9% | 379.5% | 69.2% | 65.8% | 60.1% | 65.4% |
Computed from ENVB's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ENVB valuation and financial ratios
Enveric Biosciences earned a return on equity of −420.5% in fiscal 2025. It returned $3.4 million to shareholders: $3.4 million in dividends and $0 in share buybacks.
See the ENVB income statement, the ENVB chart for price history, or the ENVB stock overview for the latest quote and news.
ENVB key metrics FAQ
What is Enveric Biosciences's return on equity?
Enveric Biosciences's return on equity (ROE) was −420.5% in fiscal 2025: net income of -$12.1 million on average shareholders' equity of $2.9 million.
What is Enveric Biosciences's current ratio?
Enveric Biosciences's current ratio was 5.38 at the end of fiscal 2025: current assets were 5.38 times current liabilities.